Acadia (ACAD): Cash-Generating CNS Franchise with Cheap Optionality — Tactical Long
Acadia trades at a reasonable entry point relative to its cash generation and conservative balance sheet. With a market cap around $4.15B, free cash flow near $198M annually, no net debt, and continued demand for central nervous system therapies, ACAD looks like an actionable long with limited downside and a clear catalyst calendar.